Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses

Equine Veterinary Journal

Volumn 44, Issue 1, 2012, Pages 107-111

  Hainisch, E K ^a   Brandt, S ^a   Shafti Keramat, S ^b   Van Den Hoven, R ^a   Kirnbauer, R ^b  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

Author keywords

Bovine papillomavirus; Horse; Sarcoid; Vaccine; Virus like particles

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL; ARTICLE; BLOOD; BOVINE PAPILLOMAVIRUS TYPE 1; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HORSE; HORSE DISEASE; IMMUNOLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BOVINE PAPILLOMAVIRUS 1; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HORSE DISEASES; HORSES; VIRAL VACCINES;

ANIMALIA; BOVINAE; BOVINE PAPILLOMAVIRUS; BOVINE PAPILLOMAVIRUS TYPE 1; BOVINE PAPILLOMAVIRUS TYPE 2; EQUIDAE; PAPILLOMAVIRIDAE;

EID: 83055188116     PISSN: 04251644     EISSN: 20423306     Source Type: Journal    
DOI: 10.1111/j.2042-3306.2011.00390.x     Document Type: Article

References (47)

1. Amtmann, E., Müller, H. and Sauer, G. (1980) Equine connective tissue tumours contain unintegrated bovine papilloma virus DNA. J. Virol. 35, 962-964.
2. Ashrafi, G.H., Piuko, K., Burden, F., Yuan, Z., Gault, E.A., Muller, M., Trawford, A., Reid, S.W., Nasir, L. and Campo, M.S. (2008) Vaccination of sarcoid-bearing donkeys with chimeric virus-like particles of bovine papillomavirus type 1. J. Gen. Virol. 89, 148-157.
3. Borzacchiello, G. and Roperto, F. (2008) Bovine papillomaviruses, papillomas and cancer in cattle. Vet. Res. 39, 45. doi: 10.1051/vetres:2008022.
4. Brandt, S., Haralambus, R., Shafti-Keramat, S., Steinborn, R., Stanek, C. and Kirnbauer, R. (2008) A subset of equine sarcoids harbours BPV-1 DNA in a complex with L1 major capsid protein. Virol. 375, 433-441.
5. Brandt, S., Tober, R., Corteggio, A., Burger, S., Sabitzer, S., Walter, I., Kainzbauer, C., Steinborn, R., Nasir, L. and Borzacchiello, G. (2011a) BPV-1 infection is not confined to the dermis but also involves the epidermis of equine sarcoids. Vet. Microbiol. 150, 35-40. doi:10.1016/j.vetmic.2010.12.021.
6. Brandt, S., Schoster, A., Tober, R., Kainzbauer, C., Burgstaller, J.P., Haralambus, R., Steinborn, R., Hinterhofer, C. and Stanek, C. (2011b) Consistent detection of bovine papillomavirus in lesions, intact skin and peripheral blood mononuclear cells of horses affected by hoof canker. Equine vet. J. 43, 202-209. doi: 10.1111/j.2042-3306.2010.00147.x.
7. Breitburd, F., Kirnbauer, R., Hubbert, N.L., Nonnenmacher, B., Trin-Dinh-Desmarquet, C., Orth, G., Schiller, J.T. and Lowy, D.R. (1995) Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69, 3959-3963.
8. Buck, C.B., Pastrana, D.V., Lowy, D.R. and Schiller, J.T. (2004) Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78, 751-757.
9. Buck, C.B., Pastrana, D.V., Lowy, D.R. and Schiller, J.T. (2008) Production of papillomaviral vectors (pseudoviruses). Last update 2008, 01.02.2009. Accessed 2009, 12/02.
10. Campo, M.S. (2006a) Introduction. In: Papillomavirus Research: From Natural History to Vaccines and Beyond, Ed: M.S. Campo, Caister Academic Press, Norfolk. pp 1-2.
11. Campo, M.S. (2006b) Bovine papillomavirus: Old system, new lessons? Papillomavirus Research: From Natural History to Vaccines and beyond, Ed: M.S. Campo, Caister Academic Press, Norfolk. pp 373-387.
12. Carr, E.A., Theon, A.P., Madewell, B.R., Griffey, S.M. and Hitchcock, M.E. (2001) Bovine papillomavirus DNA in neoplastic and nonneoplastic tissues obtained from horses with and without sarcoids in the western United States. Am. J. vet. Res. 62, 741-744.
13. Chambers, G., Ellsmore, V.A., O'Brien, P.M., Reid, S.W., Love, S., Campo, M.S. and Nasir, L. (2003) Association of bovine papillomavirus with the equine sarcoid. J. Gen. Virol. 84, 1055-1062.
14. Fermaglich, D.H. and Horohov, D.W. (2002) The effect of aging on immune responses. Vet. Clin. N. Am.: Equine Pract. 18, 621-630.
15. Hagensee, M.E., Yaegashi, N. and Galloway, D.A. (1993) Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. Virol. 67, 315-322.
16. Hainisch, E.K., Hartl, B., Kainzbauer, C., Tober, R., Shafti-Keramat, S., Kirnbauer, R. and Brandt, S. (2010) Intact BPV-1 virion is required for experimental tumour induction in foals and causes viraemia. In: Proceedings of the 26th International Papillomavirus Conference, July 3-8 2010, Montreal, Canada.
17. Joura, E.A., Kjaer, S.K., Wheeler, C.M., Sigurdsson, K., Iversen, O., Hernandez-Avila, M., Perez, G., Brown, D.R., Koutsky, L.A., Tay, E.H., García, P., Ault, K.A., Garland, S.M., Leodolter, S., Olsson, S.E., Tang, G.W., Ferris, D.G., Paavonen, J., Lehtinen, M., Steben, M., Bosch, X., Dillner, J., Kurman, R.J., Majewski, S., Muñoz, N., Myers, E.R., Villa, L.L., Taddeo, F.J., Roberts, C., Tadesse, A., Bryan, J., Lupinacci, L.C., Giacoletti, K.E., Lu, S., Vuocolo, S., Hesley, T.M., Haupt, R.M. and Barr E. (2008) HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26, 6844-6851.
18. Kirnbauer, R. (1996) Papillomavirus-like particles for serology and vaccine development. Intervirol. 39, 54-61.
19. Kirnbauer, R., Booy, F., Cheng, N., Lowy, D.R. and Schiller, J.T. (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 89, 12180-12184.
20. Kirnbauer, R., Chandrachud, L.M., O'Neil, B.W., Wagner, E.R., Grindlay, G.J., Armstrong, A., McGarvie, G.M., Schiller, J.T., Lowy, D.R. and Campo, M.S. (1996) Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virol. 219, 37-44.
21. Kirnbauer, R., Taub, J., Greenstone, H., Roden, R., Durst, M., Gissmann, L., Lowy, D.R. and Schiller, J.T. (1993) Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67, 6929-6936.
22. Lancaster, W.D. (1981) Apparent lack of integration of bovine papillomavirus DNA in virus induced equine and bovine tumour cells and virus transformed mouse cells. Virol. 108, 251-255.
23. Lindblad, E.B. (2004) Aluminium compounds for use in vaccines. Immunol. Cell Biol. 82, 497-505.
24. Marchetti, B., Gault, E.A., Cortese, M.S., Yuan, Z., Ellis, S.A., Nasir, L. and Campo, M.S. (2009) Bovine papillomavirus type 1 oncoprotein E5 inhibits equine MHC class I and interacts with equine MHC I heavy chain. J. Gen. Virol. 90, 2865-2870.
25. Mattil-Fritz, S., Scharner, D., Piuko, K., Thones, N., Gissmann, L., Müller, H. and Müller, M. (2008) Immunotherapy of equine sarcoid: Dose-escalation trial for the use of chimeric papillomavirus-like particles. J. Gen. Virol. 89, 138-147.
26. Nasir, L. and Campo, M.S. (2008) Bovine papillomaviruses: Their role in the aetiology of cutaneous tumours of bovids and equids. Vet. Dermatol. 19, 243-254.
27. O'Brien, P.M. and Campo, M.S. (2002) Evasion of host immunity directed by papillomavirus-encoded proteins. Virus Res. 88, 103-117.
28. Olsson, S.E., Villa, L.L., Costa, R.L., Petta, C.A., Andrade, R.P., Malm, C., Iversen, O.E., Høye, J., Steinwall, M., Riis-Johannessen, G., Andersson-Ellstrom, A., Elfgren, K., von Krogh, G., Lehtinen, M., Paavonen, J., Tamms, G.M., Giacoletti, K., Lupinacci, L., Esser, M.T., Vuocolo, S.C., Saah, A.J. and Barr, E. (2007) Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25, 4931-4939.
29. Otten, N., von Tscharner, C., Lazary, S., Antczak, D.F. and Gerber, H. (1993) DNA of bovine papillomavirus type 1 and 2 in equine sarcoids: PCR detection and direct sequencing. Arch. Virol. 132, 121-131.
30. Paavonen, J., Jenkins, D., Bosch, F.X., Naud, P., Salmerón, J., Wheeler, C.M., Chow, S., Apter, D.L., Kitchener, H.C. and other authors (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369, 2161-2170.
31. Pastrana, D.V., Buck, C.B., Pang, Y.Y., Thompson, C.D., Castle, P.E., Fitzgerald, P.C., Kruger Kjaer, S., Lowy, D.R. and Schiller, J.T. (2004) Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virol. 321, 205-216.
32. Pastrana, D.V., Gambhira, R., Buck, C.B., Pang, Y.-S., Thompson, C.D., Culp, T.D., Christensen, N.D., Lowy, D.R., Schiller, J.T. and Roden, R.B.S. (2005) Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virol. 337, 365-372.
33. Robl, M.G., Gordon, D.E., Lee, K.P. and Olson, C. (1972) Intracranial fibroblastic neoplasms in the hamster from bovine papilloma virus. Cancer Res. 32, 2221-2225.
34. Roden, R.B.S., Hubbert, N.L., Kirnbauer, R., Christensen, N.D., Lowy, D.R. and Schiller, J.T. (1996) Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J. Virol. 70, 3298-3301.
35. Rose, R.C., Bonnez, W., Reichman, R.C. and Garcea, R.L. (1993) Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of virus-like particles. J. Virol. 67, 1936-1944.
36. Schiller, J.T. (1997) pSHELL. Last update 1997, 30.6.1997. Accessed 2009, 12/02.
37. Schiller, J.T. (1998) pYSEAP. Last update 1998, 10.3.1998. Accessed 2009, 12/02.
38. Schiller, J.T. (2007) Papillomavirus vaccines. In: The Papillomaviruses, Eds: R. Garcia and D. DiMaio, Springer, New York. pp 337-369.
39. Scott, D.W. and Miller, W.H., Jr (2003) Sarcoid. In: Equine Dermatology, Saunders, Elsevier Science, St Louis. pp 719-731.
40. Shafti-Keramat, S., Schellenbacher, C., Handisurya, A., Christensen, N., Reininger, B., Brandt, S. and Kirnbauer, R. (2009) Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes. Virol. 393, 1-6.
41. Studer, S., Gerber, V., Straub, R., Brehm, W., Gaillard, C., Luth, A. and Burger, D. (2007) Prevalence of hereditary diseases in three-year-old Swiss Warmblood horses. Schweiz. Arch. Tierheilkd. 149, 161-171.
42. Sullins, K.E., Roberts, S.M., Lavach, J.D. and Severin, G.A. (1986) Equine sarcoid. Equine Pract. 8, 21-27.
43. Suzich, J.A., Ghim, S.J., Palmer-Hill, F.J., White, W.I., Tamura, J.K., Bell, J.A., Newsome, J.A., Jenson, A.B. and Schlegel, R. (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA 92, 11553-11557.
44. Villa, L.L., Costa, R.L., Petta, C.A., Andrade, R.P., Ault, K.A., Giuliano, A.R., Wheeler, C.M., Koutsky, L.A. and Malm, C. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6, 271-278.
45. Voss, J.L. (1969) Transmission of equine sarcoid. Am. J. vet. Res. 30, 183-191.
46. Yuan, Z., Philbey, A.W., Gault, E.A., Campo, M.S. and Nasir, L. (2007) Detection of bovine papillomavirus type 1 genomes and viral gene expression in equine inflammatory skin conditions. Virus Res. 124, 245-249.
47. Zinkernagel, R.M. (2003) On natural and artificial vaccinations. Ann. Rev. Immunol. 21, 515-546.